Benzinga | Feb 24, 2021 07:36AM EST

WPD Pharmaceuticals Announces Berubicin Supply Agreement With CNS Pharmaceuticals

VANCOUVER, British Columbia, Feb. 24, 2021 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals (CSE:WBIO) (8SV1.F) ("WPD" or the "Company") today announced that it has signed an agreement with CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS") to obtain Investigational Medicinal Product ("IMP") for use in the planned clinical trials of Berubicin. WPD will purchase half of the batch previously manufactured for CNS by BSP Pharmaceuticals for the WPD-201 and WPD-201P studies which are planned to begin in the first half of 2021. This IMP will be QP certified by Clinigen Clinical Supplies Management on behalf of WPD under European current Good Manufacture Practice ("cGMP") requirements.